HomeCompareADVM vs EPRT

ADVM vs EPRT: Dividend Comparison 2026

ADVM yields 45.87% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADVM wins by $254.3K in total portfolio value
10 years
ADVM
ADVM
● Live price
45.87%
Share price
$4.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$317.6K
Annual income
$60,065.20
Full ADVM calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ADVM vs EPRT

📍 ADVM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADVMEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADVM + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADVM pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADVM
Annual income on $10K today (after 15% tax)
$3,899.08/yr
After 10yr DRIP, annual income (after tax)
$51,055.42/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ADVM beats the other by $40,140.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADVM + EPRT for your $10,000?

ADVM: 50%EPRT: 50%
100% EPRT50/50100% ADVM
Portfolio after 10yr
$190.5K
Annual income
$36,452.96/yr
Blended yield
19.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ADVM
Analyst Ratings
10
Buy
6
Hold
Consensus: Buy
Price Target
$4.83
+10.8% upside vs current
Range: $4.00 — $5.50
Altman Z
-32.7
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADVM buys
0
EPRT buys
0
No recent congressional trades found for ADVM or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADVMEPRT
Forward yield45.87%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$317.6K$63.4K
Annual income after 10y$60,065.20$12,840.73
Total dividends collected$248.2K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$4.83$35.50

Year-by-year: ADVM vs EPRT ($10,000, DRIP)

YearADVM PortfolioADVM Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$15,287$4,587.16$11,205$505.18+$4.1KADVM
2$22,911$6,553.70$12,672$682.46+$10.2KADVM
3$33,694$9,179.50$14,490$930.48+$19.2KADVM
4$48,670$12,616.75$16,786$1,282.69+$31.9KADVM
5$69,108$17,032.01$19,753$1,791.56+$49.4KADVM
6$96,549$22,602.46$23,677$2,541.64+$72.9KADVM
7$132,818$29,511.17$29,008$3,672.99+$103.8KADVM
8$180,057$37,941.48$36,463$5,425.08+$143.6KADVM
9$240,732$48,070.97$47,238$8,221.57+$193.5KADVM
10$317,648$60,065.20$63,385$12,840.73+$254.3KADVM

ADVM vs EPRT: Complete Analysis 2026

ADVMStock

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Full ADVM Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ADVM vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADVM vs SCHDADVM vs JEPIADVM vs OADVM vs KOADVM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.